Upstream Bio (UPB) Free Cash Flow (2023 - 2026)

Upstream Bio's Free Cash Flow history runs 4 years deep, the most recent figure standing at -$47.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 16.24% year-over-year to -$47.9 million; the TTM figure through Mar 2026 stood at -$140.1 million (down 68.46% YoY), while the FY2025 annual figure was -$133.4 million, down 123.58% from the prior year.
• Free Cash Flow was -$47.9 million for Q1 2026 at Upstream Bio, down from -$30.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$8.0 million in Q2 2024 to a low of -$47.9 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$25.7 million across 4 years, with a median of -$21.1 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Free Cash Flow plunged 388.29% in 2025, then retreated 16.24% in 2026.
• A 4-year view of Free Cash Flow shows it stood at -$16.1 million in 2023, then slipped by 24.08% to -$20.0 million in 2024, then plunged by 53.78% to -$30.7 million in 2025, then slumped by 55.66% to -$47.9 million in 2026.
• The last three Free Cash Flow figures came in at -$47.9 million (Q1 2026), -$30.7 million (Q4 2025), and -$22.2 million (Q3 2025), per Business Quant data.